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Conclusions: Psychiatric disease and substance abuse are
highly prevalent among veterans with HCC. Most patients
are surviving on very meager income. These profound socio-
economic and psychosocial problems must be recognized
when providing care for HCC to this population to provide
adequate treatment and surveillance.
SATURDAY, MARCH 14, 2015,
7:30AM–9:30AM
LONG ORAL G – BASIC/
TRANSLATIONAL/EDUCATION
LO-G.01 TAUROURSODEOXYCHOLIC
ACID ALLEVIATES ISCHEMIA/
REPERFUSION INJURY IN STEATOTIC
MOUSE LIVER
C. D. Anderson, J. Zhang, N. Singh, W. Dorsett-Martin,
T. M. Earl
University Of Mississippi Medical Center, Jackson, MS
Background: Tauroursodeoxycholic acid (TUDCA)
decreases endoplasmic reticulum (ER) stress, autophagy, and
cell death in cultured rat hepatocytes. We hypothesized that
TUDCA could reduce the injury caused by total warm
ischemia reperfusion (WIR) in steatotic mouse liver.
Methods: Male ob/ob mice underwent 100% hepatic warm
ischemia by clamping the portal triad for 30 minutes. For the
experiment group, 200 mg/kg TUDCA was injected IP 1
hour before the surgery. Animals were sacrificed at 12 hours
and 48 hours after reperfusion. Quantitative real time PCR
measured ER stress markers such as C/EBP homologous
protein (CHOP), glucose regulated protein 78 (GRP78),
protein kinase dsRNA-dependent-like ER kinase (PERK),
and activating transcription factor-6 (ATF6). Western blot
examined autophagy marker microtubule-associated protein
1 light chain 3 (LC3 II). ELISA determined interleukine-6
(IL6) levels (liver and serum).
Results: Compared to controls, WIR increased ER stress in
the liver [CHOP (∼3 fold, p = 0.004), GRP78 (∼4 fold,
p = 0.001), PERK (∼2 fold, p = 0.005), and ATF6 (∼1.5 fold,
p = 0.004)] at 12 but not 48 hours. LC3 II protein levels were
increased at both 12 (∼3 fold, p = 0.019) and 48 hours (∼4 fold,
p = 0.025). Serum IL6 levels were increased at 12 (∼40 fold,
p = 0.034) and 48 hours (∼33 fold, p = 0.034). TUDCA treat-
ment decreased LC3 II at 12 (p = 0.018) and 48 hours
(p = 0.034), decreased serum IL6 at 12 (p = 0.025) and 48
hours (p = 0.025), and improved animal survival (median 26
hours vs 41 hours, p = 0.02). ER stress levels were not
changed.
Conclusion: TUDCA improves survival and reduces the
inflammation following WIR in steatotic liver through a
non-ER stress pathway.
LO-G.02 CHARACTERIZATION OF A
PORCINE MODEL FOR ASSOCIATING
LIVER PARTITION AND PORTAL VEIN
LIGATION FOR STAGED
HEPATECTOMY (ALPPS)
K. P. Croome, S. A. Mao, J. M. Glorioso, S. L. Nyberg,
D. M. Nagorney
Mayo Clinic, Rochester, MN
Background: Publications using the ALPPS procedure have
demonstrated a future liver remnant(FLR) growth of
40–160% in only 6–9 days. The present study aimed to
develop and describe the first large animal model of ALPPS
that can be used for future studies.
Methods: A total of 13 female domestic swine were studied.
ALPPS stage 1 (portal vein division and parenchymal
transection) was followed by ALPPS stage 2 (completion left
extended hepatectomy) 7 days later. An abdominal CT scan
was performed immediately prior to ALPPS stage 1 surgery
and again 7 days later to assess hypertrophy immediately
prior to ALPPS stage 2 surgery. Blood samples as well as
tissue analysis were performed.
Results: On CT volumetric analysis mean size of the FLR
prior to ALPPS stage 1 was 21.4 ± 1.8% and 39.8 ± 4.6%
prior to ALPPS stage 2. Median degree of hypertrophy was
74.5% with a median kinetic growth rate of 10.6% per day.
Liver weights at autopsy correlated well with CT volumetric
analysis(p = 0.65). There was no significant difference in
mean lab values (AST,ALT,ammonia,INR or bilirubin) from
baseline until immediately prior to ALPPS stage 2. Post
ALPPS stage 2 there was a significant increase in INR from
baseline 1.1 ± 0.1 and 1.6 ± 0.1 (p = 0.005), respectively. No
post-operative deaths secondary to liver failure were
observed.
Conclusion: The present study describes the first reproduc-
ible large animal model of the ALPPS procedure. Degree of
hypertrophy and kinetic growth rate were similar to that which
has been demonstrated in human publications. This model
will be valuable as future laboratory studies are performed.
LO-G.03 PREOPERATIVE ANAEMIA AND
POSTOPERATIVE OUTCOMES AFTER
HEPATECTOMY: A RETROSPECTIVE
COHORT STUDY
S. Tohme, P. Varley, M. Khreiss, A. Tsung
University Of Pittsburgh, Pittsburgh, PA
Background: Preoperative anemia is associated with
adverse outcomes after surgery in general but outcomes after
hepatectomy specifically are not well established. We aimed
to assess the effect of preoperative anemia on 30-day post-
operative morbidity and mortality in patients undergoing
major hepatectomies.
Methods: All elective hepatectomies for the period 2005–
2012 recorded in the NSQIP database were evaluated. We
selected to study partial lobectomies, total left, total right,
and trisegmentectomies and exclude minor procedures. We
obtained anonymized data for 30-day mortality and morbid-
ity, demographics, and preoperative and perioperative risk
factors. We used multivariate logistic regression to assess the
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adjusted and modified effect of anemia, which was defined as
(hematocrit <39% in men and <36% in women), on postop-
erative outcomes.
Results: We obtained data for 13,198 patients, of whom
4,383(33.2%) had preoperative anemia. Postoperative mor-
tality at 30-days was higher in patients with anemia than
those without anemia (odds ratio[OR]2.15,95%CI 1.70–
2.71). Morbidity at 30-days was also higher in patients with
anemia (for any complication1.93,1.79–2.09; for serious
complications 2.05,1.90–2.22). After adjustment for prede-
fined clinical and laboratory risk factors, postoperative
morbidity was higher in patients with anemia than in
those without anemia (adjusted OR any complication
1·48,1.36–1.61, serious complications 1.54,1.41–1.68). Post-
operative mortality was similar in both groups after adjust-
ment (1.09, 0.836–1.433).
Conclusion: Preoperative anemia is independently associ-
ated with an increased risk of morbidity in patients undergo-
ing hepatectomy. Therefore, it is crucial to readdress
preoperative blood management in anemic patients prior to
hepatectomy. Anemia was not an independent predictor of
mortality which may be due to the rare event of 30-day
mortality after elective hepatectomy.
LO-G.05 INTERACTION OF GLYCOGEN
SYNTHASE KINASE-3 AND NOTCH1 IN
PANCREATIC CANCER
M. Kunnimalaiyaan, S. Kunnimalaiyaan, T. Gamblin
Medical College Of Wisconsin, Milwaukee, WI
Abstract: Glycogen synthase kinase-3 (GSK-3) can act as
either tumor promoter or suppressor by its inactivation
depending on the cell type. There are conflicting reports on
the roles of GSK-3 isoforms and their interaction with
Notch1 in pancreatic cancer. We hypothesize that GSK-3α
stabilizes Notch1 in pancreatic cancer cells thereby promot-
ing cellular proliferation.
Methods: Pancreatic cancer cell lines MiaPaCa2, PANC-1,
and BxPC-3 were treated with 0–20 μM of AR-A014418
(AR). Cell growth was determined by MTT assay and
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Live-Cell Imaging. The levels of Notch pathway members
(Notch1, HES-1, survivin, cyclinD1), phosphorylated
GSK-3 isoforms, and apoptotic markers were determined by
Western blot. Immunoprecipitation was performed to iden-
tify the binding of GSK-3 specific isoform to Notch1.
Results: AR-A014418 treatment had a significant dose-
dependent growth reduction (p < 0.001) in pancreatic cancer
cells compared to control. The growth suppression effect is
due to apoptosis. Importantly, reduction in GSK-3 phos-
phorylation leads to a reduction in Notch pathway members.
Over expression of active Notch1 in AR-A014418-treated
cells resulted in negation of growth suppression. Immunopre-
cipitation analysis revealed that GSK-3α binds to Notch1.
Conclusions: This study demonstrates for the first time
that the growth suppressive effect of AR-A014418 in pancre-
atic cancer cells is mainly mediated by reduction in
phosphorylation of GSK-3α with concomitant Notch1 reduc-
tion. GSK-3αappears to stabilize Notch1 by binding and may
represent a target for therapeutic development. Furthermore,
down regulation of GSK-3 and Notch1 may be a viable
strategy for possible chemosensitization of pancreatic cancer
cells to standard therapeutics.
LO-G.06 NOVEL CONCEPT OF
ELECTROCOAGULATION & TUMOR
CELL IMPLANTATION: CREATION OF
MINIMALLY INVASIVE ORTHOTOPIC
MURINE MODEL OF PANCREATIC
CANCER
J. S. Bhullar1, Y. Cozakov1, N. Varshney2, S. Bindroo1,
S. Chaudhary1, J. Tilak3, M. Decker3, M. Jacobs1,
V. K. Mittal1
1Department Of Surgery, Southfield, MI; 2Department Of
Pathology, Toledo, OHIO; 3Department Of Patient Care
Research, Southfield, MI
Background: Orthotopic murine models of pancreatic
cancer represent an important tool for evaluating treatment
strategies. Several genetically modified mouse tumors and
xenograft models have been reported. Genetic models have
unpredictable growth & variable waiting period, while
orthotopic models are operative ones, difficult to create and
result in irregular metastasis. There is a constant endeavor to
create an orthotopic model which replicates the human
disease process.
Study Design: Orthotopic pancreatic tumors were induced
in 20 SCID mice using a novel technique. Low dose
electrocoagulation of pancreas under laparoscopic guidance
(using Coloview-mouse colonoscope) with thin electrode,
followed by injection of 0.1 cc BxPC3 pancreatic cancer
cells was done (n = 12, study group). Control mice under-
went electrocoagulation alone (n = 4, group 1) and tumor cell
injection alone (n = 4, group 2). Mice were evaluated for
tumor growth and metastasis by necropsy (4 and 8 week for
experimental group; 8 weeks for control group).
Results: Tumors were detected in 11/12 mice in experimen-
tal group, 1/4 in control group 2, and none in control group 1.
Over time there was an increase in tumor growth, tumor
volume, lymphovascular invasion of pancreas, with metasta-
sis to lymph nodes and surrounding organs.
Conclusions: We report a novel concept of tumor cell
implantation at site of electrocoagulation of pancreas. Com-
bined with the minimally invasive technique, yields a
replicative orthotopic murine model of pancreatic cancer.
Our model is minimally invasive, easy to create, and over-
comes the limitations of the existing models while questions
the possibility free floating tumor cell implantation at resec-
tion site.
LO-G.08 ADEQUACY OF HPB TRAINING:
POTENTIAL DISCONNECT BETWEEN
FELLOW AND PROGRAM DIRECTOR
PERCEPTIONS?
A. K. Bressan1, J. P. Edwards1, E. Dixon1, R. M. Minter2,
D. R. Jeyarajah3, S. C. Grondin1, C. G. Ball1
1Department Of Surgery, Foothills Medical Center And The
University Of Calgary, Calgary, AB; 2Department Of
Surgery, University Of Michigan, Ann Arbor, MI;
3Methodist Dallas Medical Center, Dallas, TX
Background: Hepatopancreatobiliary (HPB) fellowship
programs have undergone recent significant changes with
regard to training standards, case volume thresholds and
multimodality educational platforms. The goals of this study
were to (1) compare perspectives of residents and program
directors on perceptions of readiness to enter practice and (2)
identify core HPB procedures that require increased empha-
sis during training.
Methods: This survey targeted program directors (PDs) and
trainees participating in the Fellowship Council / AHPBA
pathway. Demographics, education, and career plans were
collected. A comparative analysis of PD and trainee opinions
on their confidence to perform thirteen core HPB procedures
was completed (p < 0.05).
Results: The response rate was 88% for both fellows (21/
24) and PDs (23/26). Amongst fellows, 72% believe there is
an excessive number of trainees, 81% aim to work in
university-based or academic institutions, 90% expect to
have an HPB practice combined with non-HPB cases, and
95% do not plan to pursue additional training. For all thirteen
HPB procedures, the volume of cases during training was
more often considered good or excellent by PDs than by
fellows. This difference reached statistical significance for:
major hepatectomies (PDs: 87% vs. fellows: 57%, p = .042);
pancreaticoduodenectomies (100% vs. 81%, p = .044); and
laparoscopic distal pancreatectomies (78% vs. 43%,
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p = .029). Trainees also systematically rated their confidence
to perform HPB procedures lower compared to PDs’ percep-
tion (Figure 1).
Conclusions: This study provides insight into content
domains which may require additional attention during fel-
lowship to achieve an appropriate level of proficiency and
confidence upon completion of training.
LO-G.09 WHAT TO EXPECT WHEN
YOURE EXPECTING A
HEPATOPANCREATOBILIARY
SURGEON: SELF-REPORTED
EXPERIENCE OF HPB SURGEONS FROM
DIFFERENT TRAINING TRACKS
S. G. Warner1, A. Alseidi2, J. C. Hong3, T. M. Pawlik4,
R. M. Minter1
1Departments Of Surgery And Medical Education,
University Of Michigan Health System, Ann Arbor, MI;
2Department Of Surgery, Virginia Mason Medical Center,
Seattle, WA; 3Department Of Surgery, Medical College Of
Wisconsin, Milwaukee, WI; 4Department Of Surgery, Johns
Hopkins Hospital, Baltimore, MD
Background: With a recent increase in fellowships offering
HPB training through multiple routes, prospective trainees
and employers must understand the differences between
available HPB training pathways. This study highlights self-
reported fellowship experience and current scope of practice
across 3 different training pathways.
Methods: A survey was disseminated to 654 surgeons –
active AHPBA members and recent graduates of HPB,
transplant-HPB, and surgical oncology fellowships using
SurveyGizmo®. Descriptive statistics were calculated.
Results: 416 (66%) surgeons responded. Most respondents
were male (89%), and most (83%) practice in an academic
setting. Table 1 demonstrates fellowship operative experience
and current case mix in practice. MIS training was the most
commonly identified training deficiency, with 47% HPB, 49%
transplant, and 52% SSO-trained respondents in agreement.
Ultrasound was also a commonly identified training gap with
34% HPB, 40% transplant, and 25% SSO-trained respondents
in agreement. Non-HPB cases routinely performed in practice
were most commonly GI surgery and general surgery (56% &
49%) for HPB-trained respondents, transplant and general
surgery (87% & 21%) for transplant-trained respondents, and
GI surgery and non-HPB surgical oncology (70% & 28%) for
surgical oncology-trained respondents.
Conclusions: HPB surgery fellowship training experiences
vary by training pathway, though perceived deficiencies in
MIS and US training are common across all pathways.
Despite this variability, the ultimate scope of non-transplant
HPB practice is similar across training pathways. Thus,
selection of a training pathway may best be guided by the
desired training experience and planned focus of other
components of one’s future practice.
LO-G.10 TEACHING PREOPERATIVE
PLANNING: A NEW EDUCATIONAL
INITIATIVE
N. Zilbert1, T. Lam2, S. Gallinger1, L. St. Martin2,
C. Moulton1,2
1University Of Toronto Department Of Surgery, Toronto,
ON; 2The Wilson Centre, Toronto, ON
Background: Previous research has identified the impor-
tance that expert surgeons place on preoperative planning.
Currently the teaching and assessment of preoperative plan-
ning is limited. This video demonstrates a novel education
initiative to teach surgical trainees strategies for preoperative
planning for complex HPB procedures.
Methods/Results: This video reviews one preoperative
planning module for a case of a patient with a colorectal liver
metastasis requiring a left hemihepatectomy. There are five
screens that make up the module. The introductory screen
provides a brief clinical history. The second screen allows the
trainee to review the patient’s preoperative imaging. The next
screen displays two videos of attending surgeons reviewing
the same preoperative imaging. The fourth screen displays
intraoperative video clips narrated by the operating surgeon.
Each video clip focuses on an issue that one of the attendings
on the preceding screen. The final screen shows a video from
the operating surgeon reviewing the key learning points for
the case to reinforce these for the trainee.
Conclusions: In conclusion this video demonstrates a novel
strategy for teaching preoperative planning for HPB surgery.
Following the completion of this module the trainee should
have a deeper understanding of the issues and considerations
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that are relevant for left hemihepatectomies. However the
ultimate strength of this program is that several different left
hemihepatectomy cases will be presented in the same format,
so collectively the trainee will gain a richer and more com-
plete understanding of the procedure. The process will be
repeated for the other index procedures for HPB surgery.
LO-G.11 UNDERSTANDING SURGICAL
ANATOMY OF THE LIVER: THERES AN
APP FOR THAT
L. M. Postlewait, M. Konomos, J. A. Matlock, T. White,
K. A. Delman, S. K. Maithel
Carlos And Davis Center For Surgical Anatomy And
Technique, Emory University, Atlanta, GA
Introduction: Surgical anatomy of the liver is complex and
difficult to visualize. The two-dimensional renderings avail-
able for trainees make translation to practical application
challenging. Our aim was to create an interactive App to
teach liver anatomy to improve trainee preparation for
hepatic surgery.
Methods: Liver model and animation storyboards were
created from radiographic images by a certified medical-
illustrator under the guidance of a hepatobiliary fellowship-
trained surgeon in the education center for anatomy and
simulation at the author’s institution. Animations were
completed in Adobe Photoshop and Illustrator. 3D polygonal
models were completed with detailed attention to liver shape,
vessel placement, and internal divisions. Interactivity of the
App was designed in Unity3D. The animated video models
were UVMapped and brought into Cinema 4D. The App was
designed for use on the Apple iPad.
Results: The App is an interactive model with a narrated
video to teach liver anatomy. The liver rotates in space per-
mitting a better understanding of its 3-D structure. Paren-
chyma can be removed to reveal vascular and biliary
anatomy. A narrated video provides a detailed overview of
hepatic anatomy with a logical progression from whole liver
topography sequentially down to segmental detail. Initial
feedback via internal assessment is exceptional.
Conclusions: This portable, mobile-device based instru-
ment is a novel educational tool to teach liver anatomy via an
interactive approach. Studies to assess its educational utility
are underway. Integration with cross-sectional imaging is
planned to enhance clinical applicability. The current itera-
tion is applicable for student, resident and fellow-level
trainees.
LO-H.02 RESECTION IS NOT INFERIOR
TO LIVER TRANSPLANTATION IN NODE
NEGATIVE INTRAHEPATIC
CHOLANGIOCARCINOMA
O. C. Kutlu, S. Garcia, M. V. Williams
TTU HSC Dept Of Surgery, Lubbock, TEXAS
Introduction: Intrahepatic cholangiocarcinoma(IHCCC) is
the second most common malignancy of the liver. Despite the
increasing incidence, few studies have been published on
therapeutic options and outcomes. Although survival benefits
of transplantation are well established for HCC, there is little
information on the outcomes between liver transplantation
and resection for IHCCC. In this study we investigated the
survival of IHCCC in a large population database and iden-
tified if there was a survival advantage of transplantation over
resection for stage I and II tumors.
Material Methods: SEER database was used to identify
IHCCC patients. Patients diagnosed between 1990 and 2008,
histologically proven IHCCC, T1 and T2 tumors, N zero, no
metastasis, no radiotherapy, and not lost to follow up were
included in the study. Analyses were performed using SPSS
20 with Kaplan-Meier statistics and Cox proportional
hazards regression.
Results: A total of 297 patients, 221 underwent resection
and 76 underwent transplantation met the criteria. Mean sur-
vival for resection was 36.8 months and 41.1 months for
transplantation. Survival for transplantation vs surgery is as
follows, 80% and 78% at one year, 62% and 63% two years,
54% and 51% three years, 45% and 36% four years, 28% and
36% at 5 years respectively. Survival between both groups
were similar (P = 0.29).
Conclusion: We evaluated if transplantation offered a sur-
vival benefit in patients with early IHCCC. Results showed
no difference in survival between resection and transplanta-
tion. This study questions the utility of transplantation for
stage I and II IHCC in the era of organ shortage.
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LO-H.03 A NATIONWIDE ASSESSMENT
OF OUTCOMES AFTER BILE DUCT
RECONSTRUCTION
M. F. Eskander, L. A. Bliss, O. K. Yousafzai,
S. W. De Geus, S. Ng, M. P. Callery, K. Khwaja,
J. F. Tseng
Beth Israel Deaconess Medical Center, Boston, MA
Background: Bile duct reconstruction (BDR) is used to
manage benign and malignant neoplasms, choledochal cysts
and congenital anomalies, trauma and iatrogenic bile duct
injuries, and other non-malignant diseases. We compared
BDR outcomes overall and by indication.
Methods: Retrospective analysis of Nationwide Inpatient
Sample discharges (2004–2011) including ICD-9 codes for
BDR. All statistical testing performed using survey weight-
ing. Univariate analysis of patient, hospital, admission char-
acteristics, and outcomes by indication using chi square
testing. Multivariate modeling for inpatient complications
and inpatient death by logistic regression.
Results: Identified 67,160 weighted patient discharges in
which BDR was coded: 2.5% for congenital anomaly, 37.4%
for malignant neoplasm, 2.3% for benign neoplasm, 9.9% for
biliary injury, and 48% for other non-malignant disease.
68.4% of BDR discharges for neoplasm were elective vs.
60.8% for congenital anomaly, 46.1% for other non-
malignant and 37.8% for biliary injury (p < 0.0001.) 79.8%
of neoplasm discharges were from teaching hospitals vs.
62.3% for other non-malignant disease, 65.2% for biliary
injury and 66.1% for congenital anomaly (p < 0.0001.)
33.3% of total BDR discharges involved at least one compli-
cation and 84.8% were discharges to home. Median length of
stay was 9 days (IQR 6, 15) and median cost was $22,230
(IQR 14,399, 38,358.) Significant multivariate predictors of
inpatient death include indication of biliary injury or malig-
nancy (figure), and predictors of any complication include
public insurance and non-elective admission.
Conclusion: This is the first national description of BDR
using a large database. In this diverse sampling, both pro-
cedure indication and patient characteristics influence mor-
bidity and mortality.
LO-H.04 PREDICTING LENGTH OF STAY
AND CONVERSION TO OPEN SURGERY
FOR ACUTE CHOLECYSTITIS:
VALIDATING THE 2013 TOKYO
GUIDELINES IN A US POPULATION
G. Wright1,2, M. T. Hefty1,2, K. Stilwell2, J. Johnson2,
M. H. Chung1,2,3
1GRMEP/Michigan State University General Surgery
Residency Program, Grand Rapids, MI; 2Michigan State
University College Of Human Medicine, Grand Rapids,
MI; 3Spectrum Health Medical Group, Grand Rapids, MI
Introduction: Predicting expected patient outcomes based
on disease severity is becoming increasingly important in the
US healthcare system. The 2013 Tokyo Guidelines (TG13)
for the diagnosis and severity of acute cholecystitis were put
forward by a consensus panel.
Methods: A retrospective review of patients presenting with
acute cholecystitis to a single center from 2009–2013 was
performed. The diagnosis and severity of cholecystitis were
assigned according to the TG13. The primary outcome meas-
ures were length of stay and conversion to open surgery.
Regression models were constructed for risk-adjusted
analysis.
Results: A total of 445 patients were eligible for study.
Patients were divided as follows: 137 (30.8%) grade 1, 191
(42.9%) grade 2, and 117 (26.3%) grade 3. Primary treatment
included surgery (n = 256, 57.5%), antibiotics alone
(n = 117, 26.3%), and cholecystostomy tube (n = 72, 16.2%).
For all patients, length of stay (p < 0.001), disposition to
home (p < 0.001), and morbidity (p = 0.003) were related to
increasing TG13 grade. For surgical patients, worsened out-
comes with increasing TG13 grade were seen for conversion
to open (p = 0.001), OR duration (p < 0.001), length of stay
(p = 0.009), disposition to home (p < 0.001), and readmis-
sion (p = 0.037). On multivariate analysis, TG13 grade was
an independent predictor of increasing length of stay
(p = 0.009) and conversion to open surgery (grade 2 = OR
7.63 (2.25–25.90), grade 3 = OR 24.2 (5.0–116.37)).
Conclusion: The TG13 criteria for grading acute cholecys-
titis accurately stratify patient outcomes in a US population.
Wide adoption of TG13 can better inform patients, hospital
systems, and payers of the expected outcomes of acute
cholecystitis.
LO-H.05 TARGETING DEFINITIVE
MANAGEMENT IN PATIENTS WITH
ACUTE GALLSTONE PANCREATITIS
AND CHOLEDOCHOLITHIASIS
L. C. Ewan, H. Jenkins, D. A. Subar
Department Of HPB Surgery, Blackburn, LANCASHIRE
Background: Appropriate management of common bile
duct stones in patients with gallstone pancreatitis often varies
from recommended guidelines.
Aim: To determine if patients with gallstone pancreatitis
with common bile duct stones (CBDS) were appropriately
investigated and managed according to guidelines.
Methods: This retrospective study identified 165 patients
from 2009–2013 with a first episode of gallstone pancreatitis.
Cumulative scoring (0–5) based on age >55 yrs, CBD
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>7 mm, bilirubin >22 mmol/L, ALP >200, ALT >53 was
used to predict probability of CBDS. Investigation with
either MRCP only, ERCP only, or MRCP then ERCP
was determined for each group. The presence of CBDS was
used determine whether the primary investigation was
appropriate.
Results: In the high CBDS probability group (Score
5,n = 18) 83% demonstrated a stone. 72% of this group had
ERCP directly and 28% had MRCP then ERCP. The mean
delay between MRCP and ERCP was 6.8d. For those with 4
risk factors for CBDS (n = 44) 45% were found to have a
CBDS. The majority had an MRCP before ERCP (45%),
20% went straight to ERCP and 16% had MRCP only.
Average delay to ERCP from MRCP was 5.3d (inpatients)
and 99d (outpatients). For those at low risk of CBDS (Score
0–2,n = 55), 9% had CBDS. Most underwent MRCP only
(34.5%) however 24% had ERCP of which 85% negative for
CBDS.
Conclusion: Acute gallstone pancreatitis cases predicted as
high risk for CBDS should undergo ERCP directly. For those
at moderate risk outpatient delays for MRCP should be
avoided. ERCP should be avoided in low risk groups unless
MRCP demonstrates a CBDS.
LO-H.06 BILE DUCT RESECTION IN THE
TREATMENT OF HEPATOBILIARY AND
GALLBLADDER MALIGNANCY: EFFECT
OF ASSOCIATED PROCEDURES ON
OUTCOMES
P. Shen, N. Fino, E. Levine, C. Clark
Wake Forest School Of Medicine, Winston Salem, NC
Introduction: Resection of the bile duct is required for the
treatment of cholangiocarcinoma and sometimes indicated
when resecting gallbladder and hepatic tumors.
Methods: The American College of Surgeons National Sur-
gical Quality Improvement Program Participant Use File was
used to analyze surgical outcomes in a database of patients
with hepatobiliary and gallbladder malignancies undergoing
bile duct resection with or without hepatic or vascular resec-
tion (n = 787). Patients were divided into three groups based
on type of procedure performed: 1)Bile duct resection only
(n = 289); 2)Bile duct resection with hepatic resection
(n = 454); and 3)Bile duct resection with hepatic resection
and vascular resection (n = 44). Postoperative complications
were compared between groups and regression-adjusted risk
factors were analyzed to produce observed and expected
(O/E) morbidity and mortality rates and indices.
Results: Performing additional procedures significantly
increased rates of organ space surgical site infection
(p < 0.0001), being on ventilator >48 hours (p = 0.0388),
acute renal failure (p = 0.0055), sepsis (p = 0.0292), septic
shock (p = 0.0208) and overall risk of having at least one
complication (p < 0.0001). Thirty-day mortality rates for
Groups 1, 2 and 3 were 6.23%, 8.15% and 18.18%, respec-
tively (p = 0.0242). Risk-adjusted morbidity and mortality
rates also increased when Group 1 (O/E = 1.27 and 1.64) was
compared to Group 2 (O/E = 1.61 and 2.31) and Group 3
(O/E = 1.88 and 8.00).
Conclusion: Hepatic and vascular resection significantly
increase morbidity and mortality when performed with bile
duct resection for malignancy. Patients undergoing all three
procedures experience an 8-fold increase in mortality risk
with a morbidity risk that is 2-fold higher.
LO-H.07 CLINICAL AND
PATHOLOGICAL FEATURES OF
INTRADUCTAL PAPILLARY NEOPLASM
OF THE BILIARY TRACT AND
GALLBLADDER
S. Bennett1, C. Marginean2, M. Paquin-Gobeil1,
J. Wasserman2, J. Weaver1, R. Mimeault1, F. K. Balaa1,
G. Martel1
1University Of Ottawa, Dept Of Surgery, Ottawa, ON;
2University Of Ottawa, Dept Of Pathology And Laboratory
Medicine, Ottawa, ON
Background: Intraductal papillary neoplasms of the bile
duct (IPNB) and intracholecystic papillary neoplasms
(ICPN) are rare tumors of biliary epithelium, characterized
by papillary growth within lumen that can be associated with
invasive carcinoma. Their natural history remains poorly
understood. This study examines clinicopathological features
and outcomes.
Methods: Patients who underwent surgery for IPNB/ICPN
between 2009 and 2014 were identified. Descriptive statistics
were generated.
Results: Of 23 patients found to harbor IPNB/ICPN, 43%
were male and average age was 68. Most common presenta-
tions were jaundice (43%), abdominal pain (29%), and inci-
dental ultrasound finding (14%). Preoperative ERCP with
brushing/biopsy showed at least cytologic atypia in 8/10
cases. Tumor locations were: 5 intrahepatic, 3 hilar, 8 extra-
hepatic bile duct, and 7 gallbladder. Mean tumor size
was 3.8 cm, 25% had positive lymph nodes, 47% had
lymphovascular invasion, and 37% had perineural invasion.
The R0 resection rate was 83%. The average number of
lymph nodes sampled was 4.8. Epithelial subtypes included
pancreatobiliary (52%) and intestinal (48%), and 87% dem-
onstrated invasive carcinoma, either tubular type or
mucinous. Median follow-up was 25 months. The 3-year
overall and disease-free survivals were 70% and 61%,
respectively. Of the 6 recurrences, 4 occurred in patients who
had extrahepatic bile duct cancers and 2 in gallbladder
cancers.
Conclusion: IPNB/ICPN are rare tumors that spread along
the entire biliary epithelium, including the gallbladder. At
pathology, the majority of patients demonstrate invasive car-
cinoma, thus warranting radical resection. Oncologic prog-
nosis may be superior to that of other biliary tract cancers.
LO-H.09 INTRAOPERATIVE
NEAR-INFRARED CHOLANGIOGRAPHY:
OPTIMIZATION OF TIMING AND DOSE
A. Zarrinpar, E. P. Dutson, C. Mobley, R. W. Busuttil,
C. E. Lewis, A. Tillou, A. Cheaito, O. J. Hines,
V. G. Agopian, D. T. Hiyama
Department Of Surgery, David Geffen School Of Medicine,
UCLA, Los Angeles, CA
Introduction: Intraoperative cholangiography is the gold
standard for clear delineation of biliary anatomy. However,
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logistical difficulties lead to its low utilization. Near-infrared
fluorescence cholangiography (NIRFC) with indocyanine
green (ICG) has been developed for real-time, intraoperative
biliary imaging. While several studies have shown its fea-
sibility, dosing and timing for its practical use have not been
systematically optimized.
Objective: We undertook a prospective observational study
with varying doses and elapsed times from injection of ICG
to visualization. Image quality of NIRFC and its utility to the
operating surgeon were assessed.
Methods: Adult patients undergoing laparoscopic biliary
and hepatic operations were enrolled. A single intravenous
dose of ICG (0.02–0.25 mg/kg) was administered at various
times (15–180 mins) prior to planned visualization. The
porta hepatis was examined using a dedicated laparoscopic
system. Each operating surgeon evaluated the intraoperative
recognition of biliary structures using a qualitative scoring
system (1-poor to 5-excellent). Quantitation studies were
also performed on the images obtained during the operation.
Results: Thirty-four patients were enrolled. Visualization
scores of the extrahepatic biliary tract improved with increas-
ing doses of ICG up to 0.08 mg/kg. The score also improved
with increased time up to 45 min after ICG administration.
Similarly the CBD-to-liver intensity ratio increased with
both dose and time. These results suggest that a dose of
0.08 mg/kg administered 45 minutes prior to visualization is
optimal for visualization, with diminishing improvements
with increased dose and time.
Conclusion: NIRFC is safe, practical, and effective in delin-
eating extrahepatic biliary anatomy during laparoscopic
biliary and hepatic operations.
LO-I.02 LONG-TERM OUTCOME OF
PATIENTS UNDERGOING LIVER
TRANSPLANTATION FOR MIXED
HEPATOCELLULAR CARCINOMA AND
CHOLANGIOCARCINOMA: AN
ANALYSIS OF THE UNOS DATABASE
V. Vilchez1, L. Pena2, M. Shah1, M. F. Daily1, C. Tzeng1,
D. Davenport1, R. Gedaly1, E. Maynard1
1Department Of Surgery – University Of Kentucky,
Lexington, KENTUCKY; 2Department Of Internal
Medicine-Gastroenterology – University Of Kentucky,
Lexington, KENTUCKY
Objective: To compare long-term outcomes in patients
undergoing liver transplantation (LT) for mixed hepato-
cellular carcinoma/cholangiocarcinoma (HCC-CC) versus
those with hepatocellular carcinoma (HCC) or cholangio-
carcinoma (CC).
Methods: A retrospective analysis of patients undergoing
LT for HCC-CC was performed using the United Network
for Organ Sharing (UNOS) database from 1994–2013.
Overall and disease-free survival (OS, DFS) in patients with
HCC-CC, HCC, and CC were compared.
Results: Of the 123,167 patients who underwent LT, 4,049
patients had a primary malignancy (94 HCC-CC; 3,515
HCC; 440 CC). Within the HCC-CC cohort 47(50%) had
diagnosis of HCV, compared to 1260 (35%) with HCC and
11(2%) with CC. The mean age of the patients with HCC-CC
was 57 ± 10 years and 77% were male. MELD at time of
listing did not differ among the three groups. Forty-six
percent of the patients with HCC-CC recurred. OS at 1, 3 and
5-years for HCC-CC (82%, 47%, 40%) was similar to CC
(79%, 58%, 47%) but significantly worse compared to HCC
(86%, 72%, and 62% p = 0.002). Similarly, DFS at 1, 3, and
5 years, for HCC-CC (78%, 45%, 38%) was similar to CC
(75%, 55%, 44%) but significantly worse than HCC (82%,
68%, 54%, p = 0.005).
Conclusion: LT for mixed HCC-CC have inferior OS and
DFS compared to those with HCC, suggesting that HCC-CC
outcomes more closely follow the CC phenotype. Attempts
should be made to identify HCC-CC patients prior to trans-
plant and if transplanted undergo close surveillance and con-
sideration for immunosuppression modification and/or
adjuvant therapy.
LO-I.03 LIVER TRANSPLANTATION FOR
HEPATOCELLULAR CANCER IN HIV
POSITIVE PATIENTS
N. Nissen1, R. Rogers2, B. Barin4, P. Stock2
1Cedars-Sinai Medical Center, Los Angeles, CA;
2University Of California, San Francisco, San Francisco,
CA; 4EMMES Corporation, Rockville, MD
Introduction: Liver transplantation (LT) is an excellent
treatment option for hepatocellular carcinoma (HCC) in
many patients, but whether this applies to the HIV+ patient is
unknown.
Aim: To evaluate the outcomes of LT for HCC in patients
with HIV co-infection by analyzing results of a US
multicenter trial of solid organ transplantation in HIV+
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patients. In this trial, 125 patients underwent LT between
2001 and 2007 at 11 US centers.
Methods: Database review.
Patients: Forty-five out of 125 patients (30%) undergoing
LT in this trial had HCC. These patients averaged 50 years of
age and the median native MELD at transplant was 15 (IQR
11–15). All patients were within Milan criteria at transplant
and only 1 patient had been previously downstaged. Hepatitis
C (HCV) was present in 30 of 45 patients.
Results: One and 3 year graft survivals for the HCC+/HIV+
patients were 82% and 67%, compared to 75% and 58% in
the HCC-/HIV+ patient group from the same trial (p ns).
Most grafts were lost due to HCV. At a median followup of
4.5 years, 4 patients (11%) developed HCC recurrence,
which occurred at a mean of 14 months after LT. Of the
recurrences one patient survived >24 months.
Conclusion: LT is an effective treatment for HCC in HIV+
patients, with survival rates similar to that of HIV+ patients
without HCC. Patient and graft survival are primarily deter-
mined by HCV status. HIV+ patients do not have excessive
risk of tumor progression after LT.
LO-I.04 PREDICTIVE FACTORS FOR
EXTRAHEPATIC RECURRENCE OF
HEPATOCELLULAR CARCINOMA
FOLLOWING ORTHOTOPIC LIVER
TRANSPLANTATION
A. Andreou, J. Pratschke, D. Seehofer
Department Of General, Visceral And Transplant Surgery,
Charite Campus Virchow Klinikum, Berlin,
DEUTSCHLAND
Background: Recurrence of hepatocellular carcinoma
(HCC) in patients treated with orthotopic liver transplanta-
tion (oLTX) is associated with diminished survival. Particu-
larly extrahepatic localization of HCC recurrence contributes
to poor prognosis.
Patients and Methods: Clinicopathological data of patients
who underwent oLTX for HCC between 1989 and 2010 in a
high-volume transplant center were retrospectively evaluated
and predictors of extrahepatic recurrence were identified.
Results: Three hundred and sixty-seven patients underwent
oLTX for HCC. After a median follow-up time of 77 months,
93 patients (25%) were diagnosed with a recurrence. Median
time to recurrence was 18.9 months. Recurrence was located
exclusively in the liver in 19 cases (20%) and 74 patients
(80%) had extrahepatic recurrence. Factors associated with
extrahepatic recurrence in multivariate analysis included
HCC beyond the Milan criteria (P < .0001) and the presence
of major vascular tumor invasion (MVI) (P = .035). In
patients with HCC beyond the Milan criteria who developed
a recurrence (n = 73), MVI was the only positive predictor of
extrahepatic recurrence in multivariate analysis (P = .0001).
In patients with HCC within the Milan criteria who recurred
after oLTX, DNA-index >1.5 (P = .04) was the only predic-
tive factor for extrahepatic recurrence.
Conclusions: Advanced HCC beyond the Milan criteria and
the presence of MVI are associated with an increased risk for
extrahepatic recurrence and are currently considered as
contraindications to oLTX. In patients with HCC within the
Milan criteria, the DNA-index represents a valuable prognos-
tic marker for the development of extrahepatic recurrence
and may support the selection of patients for intensive post-
operative tumor surveillance.
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OP-II.01 PANCREATIC DEBRIDEMENT
FOR NECROTIZING PANCREATITIS:
NATIONAL OUTCOMES AND
PREDICTORS OF MORTALITY
S. W. Ross, E. M. Hanna, R. C. Kirks, R. Seshadri,
J. B. Martinie, R. Z. Swan, D. A. Iannitti
Carolinas Medical Center, Division Of HPB Surgery,
Charlotte, NC
Background: Necrotizing pancreatitis often requires pan-
creatic debridement, which can result in a high rate of
morbidity and mortality. Risk factors that predispose patients
to post-operative complications or death are not well-defined.
Using a national surgical database, we sought to identify
pre-operative predictors of mortality after debridement.
Methods: The American College of Surgeon’s NSQIP data-
base was queried from 2005–2011 by CPT code for pancre-
atic debridement. Risk factors for complications and death at
30 days were examined using univariate tests and predictors
of mortality were identified using step-wise logistic
regression.
Results: 1,162 patients underwent pancreatic debridement.
On average patients were middle aged(54.9 ± 14.2 years),
male(70.0%), and obese(30.6 ± 8.0 kg/m2). The most
common comorbidities included diabetes(33.2%),
smoking(22.3%), COPD(6.5%), steroid use(4.0%) and
cardiac history (4.0%). Prior to surgery, 21.2% had ascites,
7.6% had acute renal failure, 14.7% had recent >10% body
mass loss, and 63.2% had pre-operative sepsis. Emergent
surgery occurred in 29.3%. Wound, general, and major com-
plications occurred in 7.2%, 56.6% and 31.3% respectively.
Mean length of stay was 34.1 ± 31.0 days. 30 day mortality
was 7.7%, and was higher in patients with COPD, cardiac
history, ascites, acute renal failure, steroid use, sepsis, older
age, higher BMI, and emergent operations(p < 0.05). The
table summarizes independent predictors of mortality iden-
tified using multivariate analysis.
Conclusion: Nationally, rates of adverse outcomes follow-
ing pancreatic debridement are high. Patients who are older,
with higher BMI, are on dialysis, have COPD, with
poor functional status, hypoalbuminemia, azotemia or
hyperbilirubinemia have increased odds of mortality follow-
ing debridement for necrotizing pancreatitis.
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